ArticlePharmaceutics2022

The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways.

Saverio Candido et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.